Tonix Pharmaceuticals Holding Corp. presented new clinical data for its fibromyalgia treatment TONMYA at the 8th International Congress on Controversies in Fibromyalgia held in Krakow, Poland. The company delivered two oral presentations featuring post hoc analyses from the Phase 3 RESILIENT trial and pooled data from the RELIEF and RESILIENT studies, highlighting the medication's efficacy and safety profile.
The data presented showed TONMYA, investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets), provides rapid pain relief for adults with fibromyalgia. The analysis revealed statistically significant reductions in pain and demonstrated a likelihood of clinical benefit nearly four times greater than discontinuation due to adverse events. This favorable benefit-risk profile represents a significant development for fibromyalgia patients who have had limited treatment options.
TONMYA is the first medication approved for fibromyalgia in more than 15 years, marking a substantial advancement in treatment options for this chronic pain condition. The medication was generally well tolerated in clinical studies, with mild and transient oral cavity reactions reported as the most common adverse events. The full press release detailing these findings is available at https://ibn.fm/hv3Cl.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on developing treatments for central nervous system and immunology conditions with high unmet medical needs. Beyond fibromyalgia, the company is exploring TONMYA's potential in other conditions through Phase 2 clinical trials evaluating its efficacy in major depressive disorder and acute stress disorder. The company maintains a newsroom with updates at https://ibn.fm/TNXP.
The significance of this data extends beyond clinical outcomes to address a substantial treatment gap in fibromyalgia management. With millions of patients worldwide affected by this chronic condition, the availability of a new treatment option with demonstrated efficacy and tolerability could substantially improve quality of life for those who have struggled with limited therapeutic choices. The presentation at an international congress underscores the global relevance of these findings and their potential impact on fibromyalgia treatment standards.
Tonix's broader portfolio includes additional central nervous system programs, including TNX-2900 for Prader-Willi syndrome, and immunology programs such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500 for preventing kidney transplant rejection. These product development candidates remain investigational new drugs whose efficacy and safety have not been established.
